CKBA suppresses mast cell activation via ERK signaling pathway in murine atopic dermatitis

Abstract

AbstractAtopic dermatitis (AD) is a common inflammatory skin disorder. Mast cells play an important role in AD because they regulate allergic reactions and inflammatory responses. However, whether and how the modulation of mast cell activity affects AD has not been determined. In this study, we aimed to determine the effects and mechanisms of 3‐O‐cyclohexanecarbonyl‐11‐keto‐β‐boswellic acid (CKBA). This natural compound derivative alleviates skin inflammation by inhibiting mast cell activation and maintaining skin barrier homeostasis in AD. CKBA markedly reduced serum IgE levels and alleviated skin inflammation in calcipotriol (MC903)‐induced AD mouse model. CKBA also restrained mast cell degranulation both in vitro and in vivo. RNA‐seq analysis revealed that CKBA downregulated the extracellular signal‐regulated kinase (ERK) signaling in BM‐derived mast cells activated by anti‐2,4‐dinitrophenol/2,4‐dinitrophenol‐human serum albumin. We proved that CKBA suppressed mast cell activation via ERK signaling using the ERK activator (t‐butyl hydroquinone) and inhibitor (selumetinib; AZD6244) in AD. Thus, CKBA suppressed mast cell activation in AD via the ERK signaling pathway and could be a therapeutic candidate drug for AD.